1[9]McCawley L J, Matrisian L M. Matrix metal oroteinases: multifunctional contributor s to tumor progression. Mol Med Today, 2 000,6∶149.
2[10]Ivaska J, Heino J. Adhesion recep tors and cell invasion: mechanisms of integr in-guided degradation of extracellular m atrix. Cell Mol Life Sci, 2000,57(1)∶16.
3[11]Deyugina EI, Bourdon MA, Jungwirt h K, et al. Functional activation of integri n alpha V beta3 in tunor cells expressin g membrane-type 1 matrix metalloproteina se. Int J Cancer, 2000,86(1)∶15.
4[12]Ozdemir E, Kakehi Y, Okuno H, et al. Role of matrix metalloproteinase-9 in th e basement memebrane destruction of supe rficial urothelial carcinomas. J Uro, 19 99,161∶1359.
5[13]Kanayama H, Yokota K, Kurokawa Y, et al. Prognostic values of matrix metallop roteinase-2 and tissue inhibitor of meta llproteinase-2 expression in bladder can cer, Cancer, 1998,82(7)∶1359.
6[14]Kitagawa Y, Kunimi K, Ito H, et a l. E xpression and tissue localization of mem brane-type,1,2,and 3 matrix metalloprote inases in human urothelial carcinomas. J Urol, 1998,160∶1540.
7[15]Kanda K, Takahashi M, Murakami Y, et al. The role of the activated form of ma trix mealloproteinase-2 in urothelial ca ncer. BJU Int, 2000,86∶553.
8[16]Hara I, Miyake H, Hara S,et al. Sign ificance of matrix metalloproteinases an d tissue inhibitors of metalloproteinase expression in the recurrance of superfi cial transitional cell carcinoma of the bladder. J Uro, 2001,165∶1769.
9[17]Gohji K, Fujimoto N, Ohkawa J, et al. Imbalance between serum matrix metallop roteinase-2 and its inhibitor as a predi c tor of recurrence of urothelial cancer. Br J Cancer, 1998,77∶650.
10[18]Zucker S, Hymowitz M, Conner C, et al. Measurment of matrix metalloproteinases in blood and tissues. Clinical and expe rimental applications. Ann NY Acad Sci, 1999,878∶212.
